HUMEYRA OZTURK EMRE

Dr. HUMEYRA OZTURK EMRE

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Biochemia Medica
Verified
Journal Article
Open access
PDF file
HEHUMEYRA OZTURK EMRE
HUMEYRA OZTURK EMRE
OOOzlem Goruroglu Ozturk
Ozlem Goruroglu Ozturk
ACAbdurrahman Coskun
Abdurrahman Coskun
DYDogan Yucel
Dogan Yucel
CYCevat Yazici
Cevat Yazici
FKFatma Hande Karpuzoglu
Fatma Hande Karpuzoglu
Introduction: To interpret test results correctly, understanding of the variations that affect test results is essential. The aim of this study is: 1) to evaluate the clinicians’ knowledge and opinion concerning biological variation (BV), and 2) to investigate if clinicians use BV in the interpretation of test results. Materials and methods: This study uses a questionnaire comprising open-ended and close-ended questions. Questions were selected from the real-life numerical examples of interpretation of test results, the knowledge about main sources of variations in laboratories and the opinion of clinicians on BV. A total of 399 clinicians were interviewed, and the answers were evaluated using a scoring system ranked from A (clinician has the highest level of knowledge and the ability of using BV data) to D (clinician has no knowledge about variations in laboratory). The results were presented as number (N) and percentage (%). Results: Altogether, 60.4% of clinicians have knowledge of pre-analytical and analytical variations; but only 3.5% of them have knowledge related to BV. The number of clinicians using BV data or reference change value (RCV) to interpret measurements results was zero, while 79.4% of clinicians accepted that the difference between two measurements results located within the reference interval may be significant. Conclusions: Clinicians do not use BV data or tools derived from BV such as RCV to interpret test results. It is recommended that BV should be included in the medical school curriculum, and clinicians should be encouraged to use BV data for safe and valid interpretation of test results.

1 February 2020 in Neurochirurgie
Verified
Journal Article
Closed access
AOA. Faruk Ozdemir
A. Faruk Ozdemir
RKR. Kemerdere
R. Kemerdere
BOBagnu Orhan
Bagnu Orhan
HEHUMEYRA OZTURK EMRE
HUMEYRA OZTURK EMRE
BIBerrin Bercik Inal
Berrin Bercik Inal
TTTaner Tanriverdi
Taner Tanriverdi

19 October 2020 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
BOBagnu Orhan
Bagnu Orhan
DSDerya Sonmez
Derya Sonmez
HÇHikmet Can Can Çubukçu
Hikmet Can Can Çubukçu
OZOguzhan Zengi
Oguzhan Zengi
HEHUMEYRA OZTURK EMRE
HUMEYRA OZTURK EMRE
CCCihan Coskun
Cihan Coskun
Objectives The utilization of reliable quality indicators (QIs) proven to be suitable for monitoring and improvement tools is one of the best choices to minimize of the risk of errors in all laboratory processes called as total testing process (TTP). In 2008, a Working Group “Laboratory Errors and Patient Safety” (WG-LEPS) established by International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) developed the Model of Quality Indicators (MQI) complying with requirements of the ISO 15189:2012 standard for laboratory accreditation. They have also been dealing with harmonizing the QIs in most laboratories worldwide since then. The present study was set out to investigate the frequency of using IFCC WG-LEPS’ pre-QIs by Turkish laboratories and to assess the conformity of them, by taking into account Turkey’s conditions. Methods A survey consisting nine questions was applied in 81 laboratories using SurveyMonkey. Results According to the survey results, most of the laboratories reported they have used pre-QIs in the quality standards of health prepared by Turkish Ministry of Health (MOH). A part of IFCC WG-LEPS’ pre-QIs were being utilized by more than 80% of the laboratories, the rest of which only used by 10% of laboratories. Conclusions The majority of the medical laboratories have been using the pre-QIs included in the guidelines of Quality Standards prepared by the MOH. The pre-QIs are partially compatible with IFCC WG-LEPS’ pre-QIs. The definitions of IFCC WG-LEPS’ pre-QIs may also be revised to make them more clear and understandable by IFCC WG-LEPS. The insufficiency of Health Information Management Systems (HIMS) limits the use of pre-QIs proposed by IFCC WG-LEPS. Finally, the education of relevant personnel about the use of HIMS and pre-QIs is very crucial to harmonize and to extend the use of IFCC WG-LEPS’ pre-QIs in Turkish medical biochemistry laboratories.

1 January 2017 in Surgical Neurology International
Verified
Journal Article
Open access
TTTaner Tanriverdi
Taner Tanriverdi
RKRahsan Kemerdere
Rahsan Kemerdere
BIBerrin Bercik Inal
Berrin Bercik Inal
OYOdhan Yuksel
Odhan Yuksel
HEHUMEYRA OZTURK EMRE
HUMEYRA OZTURK EMRE
SASeda Ates
Seda Ates
Endocan has been shown to be a marker for several cancers and may show degree of malignancy. The aim of this study is to assess serum levels of endocan before and after surgery on low-grade gliomas (LGGs). Endocan was assayed by commercially available enzyme-linked immunosorbent assay (ELISA) kits in a total of 19 patients and 12 controls. Serial serum samples were obtained before and after surgery (1st day, 1st week, and 1st month of surgery). Control samples were collected from cord blood during cesarean section. The results were compared with control brain tissues. Controls showed significantly lower serum endocan levels compared to before and after surgery (P < 0.05). There is a trend of increase in mean serum levels from before surgery and during the very early period after surgery (during first week); however, in the first month, mean serum levels became lower. Endocan, a vital molecule for angiogenesis, is highly expressed before and after surgery in LGGs, but long-term data is needed. Furthermore, future studies should include high-grade gliomas to discuss whether endocan is associated with recurrence and response to treatment.

1 July 2017 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
NSN.S. Samanci
N.S. Samanci
SPS. Poturoglu
S. Poturoglu
CSC. Samanci
C. Samanci
DAD. Alis
D. Alis
HEHUMEYRA OZTURK EMRE
HUMEYRA OZTURK EMRE
SOSavas Ozturk
Savas Ozturk

1 January 2026 in Journal of Medical Biochemistry
Verified
Journal Article
Open access
PDF file
HEHUMEYRA OZTURK EMRE
HUMEYRA OZTURK EMRE
NENezaket Eren
Nezaket Eren
MKMacit Koldas
Macit Koldas
Background: Paraoxonase 1 (PON1) is a calcium-dependent esterase and exerts antioxidant and antiatherogenic properties. Advanced oxidation protein products (AOPP) are a group of carbonylated protein products showing oxidant-mediated protein damage. This study aimed to determine serum PON1 activities and AOPP concentrations in diabetic patients and to evaluate these parameters in terms of their relationships with diabetes mellitus (DM) and related factors. Methods: A total of 93 patients diagnosed with type 2 DM and 30 healthy controls were enrolled in the study. Serum AOPP levels and PON1 activities were measured spectrophotometrically. Other biochemical parameters, including glucose, total cholesterol, HDL-C, LDL-C, triglycerides, HbA1c and clinical/demographic data, were measured in the routine blood chemistry laboratory and retrieved from patient files. Results: Serum PON1 activity was significantly lower in patients with DM (31.6 [21.49-48.45] U/mL) compared to controls (41.08 [29.07-54.35] U/mL) (p= 0.028). Serum AOPP concentration was significantly higher in diabetic patients (584.6 [453.8-778.6] pmol/L) than in controls (173.9 [98.77-224.1] pmol/L) (p< 0.001). PON1 activity negatively correlated with AOPP concentration and positively with serum HDL-1 levels. AOPP concentration positively correlated with age, weight, HbA1c, glucose, total cholesterol, and LDL-C. A PON1 activity cut-off of ^25 U/mL predicted DM with a sensitivity of 36.56% and specificity of 90% (AUC: 0.634, p= 0.028). An AOPP concentration cut-off of >340 mmol/L predicted DM with a sensitivity of 89.25% and specificity of 93.33% (AUC: 0.965). Both PON1 (OR: 10.821, 95% CI: 1.959-59.778, p= 0.006) and AOPP (OR: 190.068, 95% CI: 20.102-1797.148, p< 0.001) were independently associated with DM after adjusting for age, sex, and weight. Conclusions: AOPP and PON1 may play a significant role in the development and progression of DM. In particular, serum AOPP concentrations appear to be distinctive among patients with new-onset DM.